In our study population of 636 AA patients, mean age was 39.72 6 18.91 years, and the population was predominantly women (71.7%, Table I ). There was no calculable difference in cancer incidence between AA and the control group. Thyroid cancers and leukemia were noted only in the AA group, and lung cancers were present only in the control group, although these findings were not deemed statistically significant because of the low number of patients. We hypothesized that the rates of systemic malignancy would be lower in AA because of the autoimmune nature of the disease. It is known that treatment of cancers with immune checkpoint inhibitors such as tumor necrosis factor , cytotoxic T-lymphocyteeassociated protein 4, and programmed cell death protein and ligand can induce AA. 5 Induction of AA was likely due to activation of the inflammatory response and exposure of hair follicle antigens leading to loss of immune privilege. 5 Our findings call for additional, larger studies to further validate the claim that AA does not affect the risk of developing systemic cancers. These findings could potentially aid in understanding the risks associated with AA.
Strengths of our study included the presence of hair-loss specialists and a detailed AA registry. The centralized AA registry had data that was manually entered, ensuring that the relevant data were obtained for all patients. The main limitation of this study was that the cancer incidence of the control group might have differed from the general population. 
Recurrence of genital aphthosis in girls:
A retrospective analysis
To the Editor: Genital aphthosis in girls is a rare, underrecognized condition characterized by genital ulceration after an acute systemic illness. 1,2 The aphthae often are associated with severe dysuria and emotional distress in this young, adolescent population. We sought to identify disease recurrence by reviewing clinical records from January 1997 through August 2015. Institutional review board approval was obtained (IRB# 15-008638, December 2015). Inclusion and exclusion criteria, as well as a followup questionnaire, were previously published by our department.
3 Recurrence-free survival was estimated by using the Kaplan-Meier method. The follow-up duration was the date of diagnosis to the date of first recurrence or last follow-up. Associations of selected features with time to first recurrence were evaluated using Cox proportional hazards regression models and summarized with hazard ratios and 95% confidence intervals (95% CIs).
Forty-nine patients (mean age 13.8 years) met the criteria for diagnosis of genital aphthosis; of these, 10 were reported previously by our group.
3 Mean (range) duration from symptom onset to last clinical follow-up was 6.8 (0.2-18.2) years. Twenty-six patients (53%) did not have a recurrence after the primary episode. Median (interquartile range [IQR]) follow-up for these patients was 2.8 (1.3-8.6) years. At last follow-up, 23 patients (47%) had experienced recurrence at a median (IQR) of 6 (2.4-24) months after diagnosis. Seven patients had a single episode of recurrent genital ulceration, and 16 patients reported additional recurrences (2 episodes, n ¼ 10; $3 episodes, n ¼ 6). All recurrent episodes were preceded by fever or an acute viral illness. Thirteen patients (57%) had oral ulcers with the recurrence. Patients were treated with analgesics, prednisone, and topical corticosteroids, including 0.05% clobetasol propionate ointment; 4 patients required additional hospitalizations.
Estimated recurrence-free survival rate (95% CI) at 1, 2, 3, 4, and 5 years following diagnosis was 67% (55%-83%), 65% (53%-81%), 50% (37%-69%), 50% (37%-69%), and 50% (37%-69%), respectively (Fig 1) . Clinical features at primary presentation-such as age at diagnosis, preceding illness, sexual activity, or treatment category-did not affect subsequent genital ulceration rate or time to recurrence (P [ .05) ( Table I) .
A clinical history is important to rule out the presence of associated diseases (eg, systemic lupus erythematosus, Behçet disease, and Crohn disease). In the absence of these conditions, recurrence of nonsexually acquired genital aphthosis is the likely diagnosis. In 1 previous study of 12 patients (mean age at first episode 12.2 years), 7 patients were seen in a follow-up clinic, and 4 of these 7 had recurrent acute genital ulcers (range of 3-9 episodes over 2-5 years). 4 A recent report of 33 genital aphthosis cases in girls found that recurrence occurred in nearly one-third of patients. 5 In our study, 23 patients (47%) experienced recurrence at a median of 6 months, and 16 of 23 had multiple recurrent ulcerations.
Genital aphthosis in girls can cause substantial pain and great psychological stress, stigmatizing this vulnerable population. Given the rate of recurrence, anticipatory treatment plans, including systemic and topical corticosteroids and analgesics, for subsequent genital ulcerations should be considered after diagnosis. 
